PDCD1 and melanoma: In the GSE91061 melanoma cohort (Figure 6E), melanoma patients with low-PDIA3 expression had much better survival probability than patients with high-PDIA3 expression patients, and the response rate to anti-PD-1 was 17.95% in the PDIA3 high-expression subgroup, while 30% patients responded to the anti-PD1 therapy in the PDIA3 low-expression subgroup.